Education
About Us
Working with TipRanks
Follow Us
CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
CAMP Stock Chart & Stats
$3.78
-$0.13(-2.84%)
At close: 4:00 PM EST
$3.78
-$0.13(-2.84%)
Day’s Range― - ―
52-Week Range$1.31 - $7.31
Previous Close$4.45
Volume38.22K
Average Volume (3M)1.59M
Market Cap
$196.11M
Enterprise Value$10.60M
Total Cash (Recent Filing)$75.25M
Total Debt (Recent Filing)$9.39M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 26, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding51,881,134
10 Day Avg. Volume141,089
30 Day Avg. Volume1,592,597
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.61
Price to Sales (P/S)156.16
P/FCF Ratio-2.21
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue2.79
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$9.00Price Target Upside138.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ReadinessInitiation of GLP toxicology studies for CMP-002 combined with access to SynGAP natural history data should support a clinical trial filing and help with patient enrollment.
Financing And RunwayRecent financings and offering proceeds create a multi-year cash runway that enables further development of the SYNGAP-directed CMP-002 program and reduces near-term funding uncertainty.
Partnership ValidationStrategic collaboration with GlaxoSmithKline validates CAMP4's regRNA platform and provides an upfront payment plus potential milestone and royalty upside across multiple targets.
Bears Say
Clinical Data VariabilityObserved variability in CMP-001 ureagenesis results weakens confidence in consistent pharmacodynamic proof that regRNA targeting delivers anticipated biological effects.
Milestone-dependent Revenue RiskSignificant reliance on upfront, milestone and royalty payments from partnerships creates binary value drivers and limits predictable near-term revenue visibility.
Share Dilution And Market ReactionA discounted private placement pressured the share price and raised investor concerns about dilution and near-term selling pressure.
CAMP4 Therapeutics Corporation News
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $7.30 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $196.11M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
CAMP4 Therapeutics Corporation’s upcoming earnings report date is Mar 26, 2026 which is in 50 days.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
CAMP4 Therapeutics Corporation released its earnings results on Nov 20, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.072.
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate is -0.3.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 51,881,134 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
CAMP4 Therapeutics Corporation reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -17.379%.
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CAMP4 Therapeutics Corporation Stock Smart Score
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
CAMP Stock 12 Month Forecast
Average Price Target
$9.00
▲(138.10% Upside)
Technical Analysis
Relmada Therapeutics
―
Beyondspring
―
MiNK Therapeutics
―
Artiva Biotherapeutics, Inc.
―
OS Therapies Incorporated
―
Ownership Overview
28.11% Insiders
2.07% Mutual Funds
38.19% Other Institutional Investors
31.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---